NCT03934372 2025-12-17Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte CorporationPhase 1/2 Recruiting70 enrolled
NCT04233346 2025-04-04The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationOtsuka Beijing Research InstitutePhase 2 Active not recruiting93 enrolled